GlassScriptPhysician profile
Nida Arabi
NPI 1194957639
$748.14
in general payments reported to CMS, 2019-2025
14 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.68 · 2020: $15.33 · 2021: $67.51 · 2022: $218 · 2023: $183 · 2024: $92.47 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $148.50 | 2020-2023 | Veltassa |
| Baxter Healthcare | $116.93 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $91.29 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $69.63 | 2021-2024 | Farxiga |
| Ardelyx, INC. | $63.75 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $51.59 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $47.95 | 2022-2025 | |
| Travere Therapeutics, INC. | $47.64 | 2023-2025 | |
| Amgen INC. | $34.11 | 2023-2025 | Tavneos |
| Akebia Therapeutics INC | $18.89 | 2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.87 | 2025 | Jardiance |
| Lilly USA, LLC | $16.00 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $13.32 | 2022 | |
| Aurinia Pharma U.S., INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nida Arabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.